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 Callophycus serratus, a Fijian red macro alga, is the source of an interesting family 
of macrolides which have been elusive to the synthetic community. Sesquiterpene 
bromophycolides P, Q U, and related callophycolide A have highly conserved structural 
motifs which can be accessed through similar transformations therefore allowing for the 
application of a modular strategy. Formation of the modules features an expansion of 
electrophilic π-cyclizations with bromodiethylsulfonium bromopentachloroantimonate(V) 
(BDSB), and stereoselective Sharpless epoxidation and dihydroxylation conditions. 
Connection of the modules entail optimization of a magnesate assisted aryl-allyl coupling 
and a sulfone stabilized anion epoxide ring opening. The strategies explored can be applied 
to access a family of approximately 30 molecules. The development of a synthetic strategy 
is desirable due to notable anti-bacterial (MRSA and VREF), anti-malarial properties, and 
low natural abundance. Herein, I report results for the progress towards the total synthesis 










 Synthetic chemists make contributions in fields such as education, materials, and 
medicine by manipulating matter. We aim for controlled shuffling of electrons, enticing of 
charges, and exploitation of potentials to obtain coveted information or create useful 
substances. The power behind obtaining insight into the basis for chemical transformations 
propels the field forward, allowing for the development of novel reactions which produce 
compounds with a myriad of benefits. The work of synthetic chemists can lead to the mass 
production of beneficial therapeutic agents which have increased the life-span for humans 
by either being able to treat or eradicate potentially fatal ailments thereby increasing quality 
of life. 
 Many compounds that are pharmacologically relevant are born in nature and it is 
the task of the synthetic chemist to replicate what nature has evolved. There is a continual 
need for medicinal chemical innovation and the proof is in evolution. This can be described 
as a constant battle raging between humans and pathogens. Pathogens cause disease, people 
find a way to treat the disease, the pathogen evolves to evade treatment and the cycle 
continues. An example of an illness involved in the aforementioned battle which is 
currently plaguing tropical and sub-tropical regions is malaria. This thesis outlines 
synthetic strategies used to access natural products which contain anti-malarial and anti-







Malaria is a treatable and preventable illness that is transmitted by female 
Anopheles mosquitoes. The illness in humans is caused by four parasites, Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale. P. 
falciparum is the most lethal of the four and also one of the most common parasites, along 
with P. vivax.3 Transmission is prevalent globally in tropical and sub-tropical regions 
posing a risk to over 3 billion people. In 2013, malaria was estimated to afflict over 2 
million causing more than 600,000 fatalities.3d Africa is the most vulnerable region 
accounting for a mortality rate of 90%.3c, 3d African children below the age of 5 compose 
78% of malaria deaths.3d Transmission to pregnant women is a major factor for maternal, 
perinatal, and neonatal mortalities in sub-Saharan Africa.4 
 
Figure 1 Malaria life-cycle with temporal sequence. The Plasmodium parasite has three stages of 
development, a human liver stage, an erythrocytic stage (human blood cell) and an exogenous vector stage 




Malaria has three distinct stages: a human liver stage, human blood stage, and an 
exogenous stage within the vector (mosquito) (Figure 1).3c, 5 Infection begins as a 
consequence of being bitten by an Anopheles mosquito carrying Plasmodium parasites.3a, 
3c, 3d, 5 After the initial bite, the parasite undergoes an incubation period, within the human 
liver stage, which can last from 7-30 days.3b, 5-6 If someone is administered anti-malarial 
prophylaxis, the incubation period can last for weeks or months.6 The symptomatic stage 
of the illness occurs in the erythrocytic stage (human blood stage). Initial symptoms for 
uncomplicated malaria cases include: fever, chills, sweats, headache, body aches, nausea 
and vomiting.3b, 5-6 If not treated within 24 hours of exhibiting these signs and symptoms, 
infections caused by P. falciparum can result in severe illness leading to death.3b 
Many aid groups are working towards the prevention of transmission of malaria. 
Awareness of vector breeding conditions and altering living spaces to avoid said conditions 
is one route. Organizations have also made insecticides and spatial repellants available, in 
addition to insecticide treated nets.3b, 3d, 7 These methods are effective but not accessible to 
everyone in need. Other methods include intermittent and seasonal preventative treatments. 
In most cases, these preventative treatments consist of a full administration of anti-malarial 
medicines. These treatments are prioritized to high-risk groups of pregnant women and 
small children while seasonal treatments are administered during the rainy season. It also 
should be noted that as of July 2014, four vaccinations are in field clinical trials.3d 
 Despite preventative measures, transmission does still occur at staggering rates 
with tragic consequences. In many countries, the first line of defense upon parasitic 






ACTs are typically administered to children and can be distributed as pediatric 
doses. Chloroquine (1B) combination treatments (CCTs) are one of the preferred 
treatments for pregnant women (Figure 2).4 It should be noted that these therapies are not 
limited to only being administered to the age groups mentioned. Combination treatments 
are used to avert the emergence or combat the presence of Plasmodium strains that are 
resistant to chemotherapy products.3d, 4 
Plasmodium resistance to commonly used therapeutic agents was first observed in 
South-East Asia and now includes countries in Africa, South America and the West 
Indies.3d, 8 Parasites are said to have gained resistance after diagnostic tools found evidence 
of Plasmodium after the third day of receiving treatment.3d Plasmodium resistance for both 
artemisinin and chloroquine have been shown to be linked to prescription practices, such 
as administration of monotherapies, subpar medication, and sub-therapeutic levels of 
combination treatments.3d, 8a, 8b  
A retro-active case study of prescription practices in Nigeria illustrated that 
chloroquine resistance emerged as a result of private sector facilities not following World 
Health Organization dosage guidelines during a period of 1992-1997. CCTs were once the 
first line of defense in Nigeria. Now ACTs are prescribed for treatment since P. falciparum 




clinical sensitivity decreased from 100% to 40%. Investigators from this study worry about 
the clinical shelf-life of ACTs if proper dosage guidelines are not followed.8b  
Investigations into the efficacy of artemisinin in Guyana and Surinam highlighted 
the issue of counterfeit and poor quality medication, while also discussing the spreading of 
Plasmodium resistance via migrant workers.8a Spreading parasites that have built-up a 
resistance to some of the most potent drugs on the market is a real concern. A way of 
addressing single and multi-drug resistance is through the development of new treatments 
effective against Plasmodium insensitive to current clinical remedies. Many of the 
treatments currently utilized are derived from natural products.9 Compounds derived from 
natural sources may hold the key for conquering P. falciparum that have adapted resistance 








1.3 Callophycus serratus Terpenoids 
In 2005, Kubanek and coworkers described the first known occurrence of 
brominated natural products consisting of a diterpene benzoate lactone (macrolide) 
scaffold. Bromophycolide A (2), bromophycolide B (4) and debromophycolide were 
initially isolated from Fijian red macro-alga, Callophycus serratus (Figure 3). Preliminary 
bio-activity analysis indicated that bromophycolides A and B exhibit moderate anti-
bacterial activity and anti-fungal activity. Bromophycolide A is highlighted due to it being 
the most natural abundant (0.8% dry biomass) of the three terpenoids described from this 
initial investigation.10 Further extractions of C. serratus the following year illuminated the 
presence of bromophycolides C-I (3-8 and 10-11)  (Figure 3).11  
 
 
Figure 3 Macrolides belonging to bromophycolide family (A-I, S) extracted from Fijian red macro algae C. 




Delving deeper into determining the chemical constituents of C. serratus, 
investigators from the Kubanek lab isolated 10 more bio-active compounds termed 
callophycoic acids A-H (12-19) and callophycols A and B (20 and 21) (Figure 4). These 
compounds respectively contain diterpene-benzoic acid and diterpene-phenol scaffolds. 
These were the first examples of said scaffolds in macroalgae. These novel compounds 
also exhibited modest anti-malarial, anti-tumor, and anti-bacterial activity. The C. serratus 
samples used for the isolation and characterization of callophycoic acids and callophycols 
were collected at a different site in Fiji from C. serratus samples used for identification of 
bromophycolides. An interesting observation describes the lack of callophycoic acids and 
callophycols in samples containing bromophycolides, with the opposite observation also 
holding true. Therefore, where callophycoic acids and callophycols were present, 
bromophycolides were absent. This illustrates the possibility of having two chemotypes for 
C. serratus, or two cryptic species.12 
 Bio-assays were conducted to probe the biological roles of these secondary 
metabolites with the use of analytical mass-spectrometry. The bio-assays established that 
all of the bromophycolides known at this point (A-I, 2-11, and debromophycolide A) and 
some callophycoic acids (C/14, G/18 and H/19) inhibit the growth of pathogenic marine 
fungi Lindra thalassiae.12a Utilizing ambient ionization method, desorption electrospray 
ionization (DESI), researchers were able to map and quantify these secondary metabolites 
found on the surface of C. serratus with minimal or no sample preparation maintaining 










1.4 Bromophycolide Biological Activity 
Continuing into the investigation for C. serratus secondary metabolites, members 
of the Kubanek lab isolated bromophycolides J-Q (22-29) (Figure 5).  This additional study 
was prompted because LC-MS data from C. serratus extracts hinted that there might be 
more molecules not yet characterized. They speculated that these molecules contain a 
scaffold similar to the previously identified bromophycolides. Bromophycolides P and Q 
(28 and 29) illustrated a variant of the core structure consisting of a tetrahydropyran ring. 
They also exhibited potent anti-bacterial activity for methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) bacteria, in 
addition to anti-malarial activity for chloroquine-resistant Plasmodium falciparum (Table 
1).  
Other members of the bromophycolide family which do not contain a rigid pyran 
unit have less anti-bacterial activity. Alluding to the possibility that the pyran unit is 
responsible for anti-bacterial potency. Results indicating potent anti-malarial activity, 
prompted the investigators to check P. falciparum inhibition for bromophycolides 
previously described.13a Comparison of inhibitory activity and the carbon frame showed 
that the macro-cycle is essential for anti-malarial activity. Bromophycolides are more 







Figure 5 Diterpene benzoate lactone macrocyclic natural products associated with bromophycolide family 
extracted from Fijian red macro algae C. serratus.13, 15 
 
Four more bromophycolides (R/32, T/31, U/30) were reported in the subsequent 
year, expanding the array of bio-active molecules known for C. serratus (Figure 5). 
Notably, bromophycolide U, exhibited potent anti-malarial activity for chloroquine-
11 
 
resistant P. falciparum. Sub-micromolar anti-bacterial activity for MRSA and VREF were 
also observed for bromophycolide U which also contains a pyran unit similar to previously 
identified bromophycolides P and Q that exhibited similar bio-activity. 15a Of the 
bromophycolides identified, bromophycolides Q and U exhibit the widest range of 
pharmacological activity containing notable inhibitory potencies for chloroquine-resistant 
P. falciparum (anti-malarial), MRSA (anti-bacterial), and VREF (anti-bacterial). 
Bromophycolides P, Q, and U also exhibit a synthetically interesting scaffold of a di-
terpene benzoate macrolide with a pyran moiety.13a, 15a 
 
Table 1 Bromophycolide family bio-activity profile featuring inhibitory concentration (IC50) values for 
chloroquine resistant P. falciparum, methicillin-resistant Staphylococcus aureus (MRSA), and 





















A 0.5 5.9 5.9 L 9.8 8.2 26 
B 4.8 5.9 3.0 M 0.5 6.7 21 
C 56 - - N 1.4 7.2 56 
D 0.3 - - O 1.4 8.9 18 
E 0.8 - - P 2.9 1.4 13 
F 18 - - Q 1.4 1.8 5.8 
G 14 - - R 1.7 >15 >15 
H 0.9 - - S 0.9 >15 3.8 
I 2.5 - - T 8.4 >15 >15 
J 2.7 80 66 U 2.1 0.9 0.9 
K 44 - -     
 
Bromophycolide D is the most potent anti-malarial and bromophycolide A exhibits 
sub-micromolar activity along with being the most naturally abundant (Table 1).10a, 11, 13a 
Bromophycolide A is the most studied molecule in the family due to its relatively high 
natural abundance (0.8% dry bio-mass) and strong potency (IC50 = 0.5 μM).
10a, 13a, 15b, 16 
Studies were conducted on bromophycolide A and semi-synthetic derivatives to determine 
the mode of action (MOA) for anti-malarial activity (Figure 6). Co-localization studies 
12 
 
conducted with derivatives of bromophycolide A containing a fluorescent tag (34 and 35) 
illustrated that bromophycolide A  disrupts heme crystallization while the parasite is in the 
erythrocytic stage (Figure 1).15b This is the same MOA for chloroquine based treatments.17 
Notably, some of the semi-synthetic derivatives also exhibit anti-malarial potency greater 
than bromophycolide D, the most potent in the family of compounds.15b
 
Figure 6 Image features semi-synthetic derivatives from heme crystallization MOA study with chloroquine 
resistant P. falciparum inhibitory concentration values. Modifications from semi-synthesis are highlighted in 
red. FP = Fluorescent appendage.13,15 
 
While in the erythrocytic stage (Figure 1), P. falciparum consumes heme in its food 
vacuole. The parasite forms crystalline heme (hemozoin) to circumvent toxicity of free 
heme.18 Therefore, disruption of hemozoin formation has therapeutic benefits since it is 
detrimental to the life-cycle of the parasite. P. falciparum has developed a resistance to 
chloroquine based therapies by adapting integral membrane proteins that selectively lower 
the concentration of chloroquine in the parasites food vacuole where it is needed most.19 
Members of the bromophycolide family have demonstrated inhibition of P. falciparum that 
have evolved a resistance to chloroquine.13, 15 
13 
 
Pharmacokinetic profiles were established for bromophycolide A in pursuit of 
possible medicinal application. Murine studies showed that bromophycolide A is non-toxic 
and quickly eliminated from blood. Further tests established that bromophycolide A is 
metabolized by liver enzymes therefore limiting therapeutic bio-availability. Synthetic 
derivatives of bromophycolide A could address clearance issues pertaining to liver 
metabolism. Surprisingly, the lactone is not susceptible to degradation in the liver. 
Investigators suspect that hydroxylation within the liver, especially on the benzoate ring, 
contributes to degradation. Hence, they propose installation of electron withdrawing 
groups, such as halogens, to prevent said hydroxylations. Also, previous semi-synthetic 
SAR studies illustrated the importance of the phenolic group for anti-malarial activity. 
Researchers also proposed protection of the hydroxyl group so it is less susceptible to 













1.5 Thesis Overview 
 
Chapter 2 
 Previous attempts at the synthesis of the bromophycolide scaffold is presented in 
Chapter 2. A key transformation which allows for the construction of the cyclohexyl unit 
is a bromonium polyene electrophilic -cyclization using Snyder’s reagent, BDSB. 
Background information on the aforementioned transformation is presented. The synthetic 
strategy adopted for the synthesis of molecular targets bromophycolides P, Q, U and 
callophycolide A is also discussed. A modular strategy was adopted and a modular 
retrosynthetic plan is outlined for the reader. A significance of using a modular approach 
include facile formation of pharmacologically and synthetically interesting derivatives. 
Subsequent sections present results for module formation and methods explored for the 





2.1 Bromophycolide Synthetic Strategy 
 
Structurally fascinating, the scaffold for the bromophycolide family has an almost 
intimidating allure for synthetic organic chemist. Consisting of multiple stereogenic 
centers (some of which are brominated), selective olefination, in some cases a pyran or 
epoxide moiety, and a highly conserved benzoate lactone system, this family is 
synthetically challenging to access with the efficiency nature has exhibited. Lin and 
coworkers (2011) have attempted to complete the synthesis of bromophycolides A and D 
(2 and 6) (Figure 7). They were able to access the carbon skeleton in six steps. However, 
completion was not attained due to difficulty in formation of the bromohydrin.20  
 
 








2.1.1 Bromonium Electrophilic -Cyclization 
 
Additionally, for the first attempted synthesis of bromophycolide A yields were low 
for the bromonium electrophilic -cyclization step using Snyder’s reagent 
(bromodiethylsulfonium bromopentachloroantimonate, BDSB, 40) (Figure 8).1, 20 The 
transannular synthetic strategy adopted for the initial attempt was not modular and began 
with a benzoate geranylgeranyl system with subsequent formation of the macro-cycle 
before bromonium electrophilic -cyclization.20 Notably, yields for reactions of this class 
are inherently low with Snyder’s bromonium source being the most efficient (Table 2 and 
Figure 8). BDSB is commercially available but can also be prepared rather easily.1  
 
Table 2 Adapted from Snyder’s BDSB study, table shows comparison of bromonium sources  







Despite the relative superior efficiency for BDSB as a bromonium source, the 
reaction for polyene systems does still have other limitations. The BDSB polyene 
electrophilic -cyclization is dependent on concentration and requires dilute conditions 
(Table 3). Table 3 also illustrates how yields diminish when the reaction is scaled up, 
favoring formation of the major equatorial diastereomer. The scope presented in Snyder’s 
Figure 8 Snyder’s 
Reagent (BDSB) 1 
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report is also limited. It lacks demonstration of incorporating functionality at the equatorial 
methyl group of the geminal system.1 Addition of a functional group at this position could 
be useful for applications concerning the total synthesis of natural products.  
Table 3 Adapted from Snyder’s BDSB study, table shows concentration study for BDSB model system 
geranyl acetate. Image also provides description of diastereomeric products.1 
 
 
Entry Scale [mmol] Conc. [M] BDSB equiv. Yield [%] d.r. 
1 0.1 0.100 1.0 80 3.8:1 
2 0.5 0.100 1.0 61 4.3:1 
3 0.5 0.025 1.0 70 4.7:1 
5 0.5 0.025 1.1 74 4.3:1 
6 0.5 0.010 1.0 78 5.1:1 
7 0.5 0.010 1.1 84 5.0:1 







Despite the pitfalls concerning polyene electrophilic -cyclizations, the 
transformation is synthetically useful. Figure 9 is an illustration of a general mechanism. 
Stereochemistry is established via adoption of a chair-like transition for bromonium 
Figure 9 Mechanistic description for BDSB 
polyene electrophilic -cyclization 
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addition. Equatorial bromination and hydration occurs as a result of a syn-periplanar orbital 
alignment. Considering these limitations, the objective of this thesis is reporting progress 
on the total synthesis of bromophycolides P, Q, U, and derivatives incorporating a 
methodology development to increase the scope of substrates for BDSB polyene 
electrophilic -cyclization. 
 Extracts of bromophycolides P, Q, and U (28-30) exhibit notable inhibition for 
chloroquine resistant P. falciparum. 29 and 30 also exhibit potent inhibition for MRSA, 
and VREF. Analysis of synthetic bromophycolides P, Q, and U should exhibit the same 
bio-activity as their naturally occurring counterparts. Synthetic derivatives of these natural 
products obtained via utilization of a modular approach will add to a bio-activity profile 
which currently is composed of information obtained from natural extracts and semi-
synthetic derivatives. Additionally, structure activity relationship (SAR) studies will also 
be conducted on synthetic bromophycolides P, Q, U, and derivatives. 
2.1.3 Significance- Modular Approach  
 
The rise of pathogens which have evolved resistance to commonly used therapeutic 
agents is indicative of a need for the development of new compounds effective against 
pathogens insensitive to therapies on the market.3d, 4, 8-9, 13b, 21 Bromophycolides with a 
pyran incorporated into their scaffold (especially bromophycolides Q and U) have 
exhibited notable inhibitory potency chloroquine resistant P. falciparum, MRSA and 
VREF. Natural abundance for these bio-active compounds are low: bromophycolide U 
(0.0049% of dry biomass), bromophycolide Q (0.023% of dry biomass), bromophycolide 
P (0.092% of dry biomass).13, 15a These bromophycolides have a broad pharmacological 
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profile, low natural abundance, and an intriguing molecular scaffold. Consideration of 
these factors exhibit the necessity for pursuing the completion of a synthetic route to 
efficiently access gram-scaled quantities of the listed bromophycolides. 
A modular approach for the synthesis of bromophycolides P, Q, and U allows for 
formation of derivatives (Figure 10). A similar approach was utilized to access 
Callophycolide A, a C. serratus natural product which contains similar structural motifs as 
the target bromophycolides P, Q, and U (Figure 11). Callophycolide A does not contain 
the same bio-activity as bromophycolides P, Q, and U. However, methods used to access 
this less complex scaffold are applicable to the synthesis of desirable bromophycolides 
with useful bio-active properties.   Derivatives can be screened for bio-activity and SAR 
studies conducted. The three bromophycolides (P, Q and U) which this study focuses on 
have scaffolds which are highly conserved. The only difference between the three 
structures is the location of the alkene associated with the cyclohexyl moiety. Selective 
olefination and formation of the cyclohexyl group allows access to other C. serratus 
terpenoids, therefore expanding the scope of this synthetic endeavor. Optimization of 
BDSB polyene electrophilic -cyclization by introduction of functionality to expand the 











Figure 10 Modular approach to the synthesis of 
bromophycolides P, Q, and U. The macrolide is 
sectioned off into three pieces so conditions can be 
optimized individually. Upon completion, the 
segments will be joined. The cyclohexyl ring (A, 
red) is using a descriptor to symbolize that 
selective olefination can access the 
bromophycolides P, Q, and U. 
Figure 11 Modular approach used to access Callophycolide A, 
a C. serratus natural product. Methods utilized and optimized 
using this route are applicable to accessing other pertinent 





Recognizing the versatility of utilizing a modular approach, the scaffold for 
bromophycolides P (28), Q (29), U (30) was divided into three parts (Figure 10). The 
modules and attachments points for precursors are color coded in an attempt to clarify 
structural modifications and keep sight of the end-game objective. Upon consideration of 
possible disconnections to obtain viable precursors with compatible transformations, it 
becomes evident that the benzoate moiety (blue) can link to the cyclohexyl (A, red) via 
aryl-alkyl Suzuki coupling. The benzoate (C, blue) can also link to the pyran (B, green) via 
an esterification, possibly under Steglich conditions. While the cyclohexyl (red) and pyran 
(green) can either undergo alkyl-alkyl coupling (recently developed chemistry) or possibly 












2.2.1 Cyclohexyl Formation- Bromophycolides P, Q, and U 
 
 
Figure 12 Retrosynthesis for the formation of the cyclohexyl unit of Bromophycolides P, Q, and U 
 
 
Strategies adopted and employed should be efficient, address asymmetric needs by 
induction of chirality, tolerant of functional groups (chemoselectivity), and regioselective 
when necessary. Figure 12 is an illustration of the retrosynthesis of the cyclohexyl module 
for target macrolides from terpene starting material. Figure 13 outlines the strategy used to 
access the cyclohexyl moiety (A, red). Beginning with commercially available geraniol 
(42), functionality will be introduced at position “X”. These groups (43, 36, and 38) are 
highlighted in blue to show connection to the benzoate unit (C).  
Allylic oxidation of the model system, commercially available geranyl acetate (36), 
produces compound 44. The geranyl acetate allylic alcohol is an ideal precursor for 
introduction of functionality at the “Y” position. Functional groups at the “Y” position are 
highlighted in green to indicate that it is the point of attachment to the pyran moiety (Figure 
12, green). Compounds 45 – 49 in Figure 13 are the precursors for the bromonium 
electrophilic -cyclization using Snyder’s reagent (40, Figure 8). Various functional 
groups were selected for both the “X” and “Y” position in order to investigate which system 
was most compatible with the strongly electrophilic bromonium source. Factors considered 
for compatibility would include tolerance to the transformation and increased yields. 
Compound 50 is an illustration of the general form for the cyclized product which will then 
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undergo selective elimination of the tertiary alcohol to form di- (51), tri- (52), or tetra-
substituted (53) alkenes. 
 
 
Figure 13 Synthetic outline featuring substrates screened for formation of the cyclohexyl moiety (A, red). 






Figure 14 Experimental data for the synthesis of cyclohexyl (A, red, Figure 10) precursors.1, 22-23 
 
Conditions and yields for the introduction of various functional groups at the “X” 
position (blue) are provided in Figure 14. Deprotonation of 42 with triethylamine (TEA) 
and catalytic 4-(dimethylamino)pyridine (DMAP) in dichloromethane (DCM) then drop 
wise addition of trifluroacetic anhydride (TFAA) produced compound 38.1 The product 
was bright pink (as described in literature), and 1H-NMR of the crude showed almost full 
conversion to the desired product. However, efforts to purify the product via column 
chromatography (silica stationary phase) and vacuum distillation were unfruitful. Similar 
conditions were used for the synthesis of compound 36 (42, TEA, DMAP, and DCM). The 
acylating agent for this reaction was acetic anhydride.1 Conversion to the product and 
isolation occurred smoothly with a 90% yield. 3,4-Dihydro-2H-pyran, para-
toluenesulfonic acid monohydrate in DCM was combined with 42 to form tetra-
hydropyran (THP) ether 43 in excellent yields (92%).22  
25 
 
Bromonium -electrophilic cyclization was attempted with substrates 36 and 43. 
Geranyl acetate (36) was selected as a model system since there is precedent for this 
transformation in the literature. Concentration studies were conducted to determine the 
optimal concentration to perform this reaction with the most amount of starting material 
(Table 4, entries 1-7). Electrophilic cyclization yields tend to diminish once the reaction is 
scaled up (Table 4, entry 8). To counter this limitation, the reaction must be extremely 
dilute. Table 4 entry 5 indicates the optimum concentration for scaling the reaction up 
without excessive yield decrease. Cyclization of 43, resulted in degradation of the starting 
material (Table 4, entry 10). Specifically, the bromonium source was cleaving the THP 
ether and forming geraniol (42).  
Due to tolerance for the BDSB cyclization, geranyl acetate (36), was selected for 
the continuation for the synthesis. The next step involved an allylic oxidation using 
selenium dioxide (SeO2), salicylic acid, DCM, and t-butyl hydrogen peroxide (TBHP) to 
form 44 (Figure 14).23 The literature method was not clear as to what the TBHP was 
suspended in (nonane or water). Further investigation showed that better yields were 
slightly better accomplished using the water suspension (49% yield). Further investigation 
illustrated that yields diminish significantly to 36% when the reaction is conducted on a 









Table 4 Bromonium -electrophilic cyclization using Snyder’s reagent (BDSB, 40). Optimization table 
includes data for concentration dependence study in addition to results for the cyclization of substrates with 





Conditions: BDSB (1.1 eq), Stirring for 5 minutes; *Stirring for 10 minutes 
 
Acquiring sufficient quantities of the allylic oxidation product of geranyl acetate 
(44) allowed for test reactions to be conducted to further modify said terminal position 
(Figure 15). Attempts to isolate 45 from 44 were unsuccessful after formation using TEA 
and para-toluenesulfonyl chloride (TsCl) in DCM. 2-D Thin-layer chromatography (TLC) 







69% 53% 16% 
2 1mmol 0.03 37 41% 41% 0% 
3 1mmol 0.05 37 54% 40% 14% 
4* 1mmol 0.05 37 46% 46% 0% 
5 1mmol 0.07 37 58% 42% 16% 
6* 1mmol 0.07 37 29% 29% 0% 
7 1mmol 0.09 37 38% 38% 0% 

















































alludes to suspicion that the allylic tosylate is unstable on silica gel which resulted in 
degradation during column chromatography. Following a procedure from the literature, 
compound 47 was formed from 44 in excellent yields, 93%. This transformation involved 




Figure 15 Description of conditions used to functionalize the allylic “Y” position (green). 2 
 
Attempts to generate -electrophilic cyclization substrate 46 using the same 
principles for acquiring substrate 47 resulted in low yields, 16% (Figure 15). Conversion 
to the allylic sulfone (46) was accomplished efficiently (95% yield) via a SN2 displacement 
of allylic bromine 47 with sodium sulfinate in dimethylsulfoxide. There is no known 
literature precedent for the formation of 46. Accessing the allylic dimethylphenylsilane 
proved unsuccessful due to inability to form a Grignard from 47 (Figure 15). Various 
methods were tried to generate the Grignard including using different magnesium sources, 
treatment of the magnesium with 1 M HCl and ethanol, use of initiators such as crystalline 
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iodine, and consideration of weather conditions (preparation and reactions conducted on 
days with low humidity). 
Successful acquisition of gram-scale quantities of substrates 47 and 46 allowed for 
test reactions to probe BDSB -electrophilic cyclization reactivity. Subjecting allylic 
brominated substrate 47 to cyclization conditions resulted in formation of the alcohol 
which degrades to the tri-substituted alkene 54 with modest yields, 35% (Table 4, entry 9). 
Formation of cyclized sulfone 55 from substrate 46 was accomplished with relatively good 
yields, 75% (Table 4, entry 11). Similar to the allylic bromide system (47 -> 54), 
cyclization of the sulfone also produces the tri-substituted alkene. The tri-substituted 
alkene is found in target bromophycolide U. Considering the promising yields for 
formation of cyclized sulfone 55, the synthetic strategy to access the bromophycolide 
cyclohexyl are outlined in Figure 16. 
 
 





As previously demonstrated in Table 4, geranyl acetate (36) is also used as a model 
system for probing selective tertiary alcohol elimination (Table 5). This elimination study 
was done in parallel with the determination of which terminal functional groups would be 
ideal for the bromonium -cyclization. Initial attempts to use Swern oxidation conditions 
to facilitate the elimination resulted in diminished yields, 32%, and a less than ideal product 
distribution.24a Modifications to the conventional Swern oxidation to facilitate elimination 
includes significant increase of equivalence of oxalyl chloride (COCl)2, DMSO and 
TEA.24b These modifications resulted in a significant increase in yield to 73% and a slight 
preference for the formation of the exo-cyclic alkene. When the alcohol is equatorial, the 
elimination favors formation of an exo-cyclic alkene (51). Figure 17 provides a mechanistic 
description for the product distribution noted in Table 5. When the alcohol is equatorial, 
the sulfur ylide is anti-periplanar to the geminal axial methyl. This desirable orbital overlap 
favors formation of the exo-cyclic alkene reflected in product distribution. 52 experiences 
allylic 1,2-strain (A1,2) and contains significant equatorial steric congestion which is 
reflected in the product distribution. 




Conditions Total Yield Exo- Tri- Tetra- 
Swern Oxidation: 2.4eq (COCl)2, 5eq TEA, 4.8eq 
DMSO 32% 1.4 1.6 1.0 
Swern Elimination: 5.3eq (COCl)2, 24eq TEA, 9.5eq 
DMSO 73% 3.2 1.1 1.0 
Amberlyst-15 dry, DCM (18 hrs) 24% 2.0 1.0 0.0 
Amberlyst-15 dry, 4Å DCM (18 hrs)  36% 4.5 8.0 1.0 
Amberlyst-15 dry, reflux, DCM (18 hrs)  54% 1.0 3.0 0.0 
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Amberlyst-15 dry is a sulfonic acid based heterogeneous reusable catalyst which 
facilitates the dehydration of tertiary alcohols. This elimination has demonstrated 
selectivity for the tri-substituted olefin (53).24c Reactions seem to proceed to completion 
when analyzed via TLC (starting material seems to be fully consumed). However, yields 
are low (maximum yield: 54%) indicating that product is being lost along the way, probably 
during the work-up (Table 5). Some additional elimination methods include use of 
Burgess’s reagent, mild Brønstead acids, Lewis Acids (BF3•Et2O), and pyrolytic syn-
elimination reactions (xanthate chemistry: Chugaev reaction). 
 
 







2.2.2 Aryl-Allyl Cross-Coupling 
 
 
Figure 18 Retrosynthesis for the connection of aryl and terpene units.  
  
 Continuing on the road towards accessing the scaffolds of bromophycolides P, Q, 
U and callophycolide A using the modular strategy outlined entailed determining a method 
for joining the benzoate and geranyl fragments (Figure 18). Three methods to perform the 
aforementioned aryl-allyl coupling were explored. Attempts to make geranyl substrates for 
Stille and Suzuki were explored but not fully developed either due to difficult preparation 
or avoidance of using highly toxic reagents which were difficult to purify.29, 30 Figure 19 
outlines initial attempts to produce geranyl stannane and geranyl pinacol boronate. 
Compound 57 was difficult to purify from residual tributyltin chloride (TBTC) and geranyl 
bromide via vacuum distillation after multiple attempts. Formation of 58 did not occur 





Figure 19 Scheme outlining initial attempts to access precursors for Stillie and Suzuki aryl-allyl cross 
coupling. 29, 30   
 
 Scouring the literature revealed a source for the desired aryl-allyl cross coupling 
using a magnesate complex generated from a Grignard and organolithiate. Pursuing this 
route was beneficial due to my ability to replicate the conditions outlined and my ability to 
optimize the transformation for systems pertinent to accessing C. serratus natural product 
scaffolds. The model system outlined in Figure 20 illustrates cross-coupling of para-
bromo-tert-butyl benzoate (60) with allyl bromide (61) to provide compound 62 in decent 
yields, 51%. The magnesate complex allows for sufficient activation of the aryl bromide 
substrate and the presence of the tert-butyl group prevents nucleophilic addition to the 
ester.31, 32   
 




 Successful acquisition of coupled product 62 in Figure 20 prompted the application 
of the transformation towards accessing coupled products which could be applied to the 
formation of natural product targets bromophycolides P, Q, U and callophycolide A. The 
two routes initially explored involved determination if the tert-butyl group was necessary 
for the prevention of nucleophilic addition to the ester. The sequence outlined in Figure 21 
illustrates the formation of 4-hydroxymethylbromobenzoate 64, 88% yield, and 4-hydroxy-
tert-butylbromobenzoate 66, 88% yield.  Which were then protected with triisopropyl 
silane forming compounds 65 and 67 with quantitative recovery of the desired products. 
Conducting the aryl-allyl coupling with geranyl bromide and compound 65 resulted in an 
undecipherable mixture and not the desired product. Subjecting geranyl bromide and 
compound 67 resulted in migration of the triisopropyl silane protecting group, 68, 89% 
yield. Considering the electronic implications of having a highly anionic charge adjacent 
to a silyl ether, it is not shocking that the migration occurred.     
 
Figure 21 Scheme outlining initial attempts towards accessing aryl-allyl cross coupled products for target 




 Migration of the TIPS protecting group (68, Figure 21) during the allyl-aryl 
coupling event was prevented with the use of a methyl ether protecting group in subsequent 
reactions. The methyl ether protecting group on the tert-butyl benzoate substrate (69, 
Figure 22) was obtained in excellent yield, 97%, after an evaluation of different conditions. 
Obtaining nearly quantitative yield for 69 required the use of a staggering 10 equivalence 
of methyl iodide with potassium carbonate in acetone. Subjecting 69 to the in situ generated 
magnesate complex in the presence of geranyl bromide (56) did finally provide the desired 
product which can be utilized to access natural product target bromophycolides P, Q, U 
and callophycolide A (Figure 22).  
   
 
Figure 22 Scheme illustrates initial conditions for accessing the desired geranyl-aryl coupled product. 




 These results were promising however further probing and optimization was 
necessary due to my observation of the formation of a deleterious side product (71/B Table 
6) which makes purification of the desired product difficult due to similar retention factor 
values in various solvent systems.  Compound 71 was verified by isolation using 
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preparative TLC. Table 6 (entry 4) shows that the best conditions which reduce the 
formation of undesirable compound 71 entail allowing the organometallic complex to form 
for 1 hour and the coupling event with geranyl bromide to stir for 0.5 hour and the use of 
Li2CuCl4 as the copper source. Entries 1-3 from Table 6 demonstrated formation of the 
coupled product however, the presence of the quenched aryl substrate made these 
conditions less favorable. Although the aryl substrate, 69, is formed in quantitative yield 
with a near pristine crude 1H NMR spectrum, without purification, the product distribution 
ratio shifts in favor of the formation of undesirable aryl species 71 (Table 6, entry 5). 
 A screen of Grignard reagents was also performed (Table 7). Results show that 
isopropenyl magnesium bromide is more efficient and provides a more clean reaction 
(Table 7, entry 2). Table 8, entry 6 shows that the optimal concentration to conduct the 
reaction on is 0.3 M of THF. Entries 10 and 11 are control reactions which confirm the 
need for the both the Grignard reagent and n-BuLi for the reaction to proceed. Attempts in 
increase the yield by allowing the reaction to gently warm to room temperature thereby 
driving the reaction to completion were also unsuccessful and resulted in diminished yields. 
Figure 23 shows an attempt to discern what was quenching the reactivity of the aryl halide 
to form 71. This was accomplished by quenching the optimized aryl-allyl coupling 
conditions with deuterium oxide and observing where deuterium was incorporated. Results 
illustrated that deuterium was only incorporated into the aryl halide and not in the desired 
product. This quelled speculation that the active aryl magnesate complex was 






Table 6 Optimization of the time needed for the generation of the aryl organometallic complex (Grignard/ in 
situ generated magnesate complex) and the actual coupling event with geranyl bromide. An overarching goal 
of this screen was to find conditions which reduced the formation of compound 71 (B).  
 
 
 Time (Hr)   
Entry Grignard GBr Yield, A+ B (%) A B 
1 0.5 0.5 64 1 0.28 
2 1 1 59 1 0.25 
3 0.5 1 38 1 0.33 
*4 1 0.5 59 1 0.11 
**5 1 0.5 52 0.56 1 
*Li2CuCl4 used instead of CuCN●2LiCl; ** Aryl halide not columned before use, and different set of NMR 
peaks used in ratio. 
 
 
 Attempts in increase the yield by allowing the reaction to gently warm to room 
temperature thereby driving the reaction to completion were also unsuccessful and resulted 
in diminished yields (Table 8, entries 12 and 13). Figure 23 shows an attempt to discern 
what was quenching the reactivity of the aryl halide to form 71. This was accomplished by 
quenching the optimized aryl-allyl coupling conditions with deuterium oxide and 
observing where deuterium was incorporated. Results illustrated that deuterium was only 
incorporated into the aryl halide and not in the desired product. This quelled speculation 
that the active aryl magnesate complex was deprotonating the benzylic/allylic proton in 70 











Entry Grignard Reagent Isolated Yield (%) 
1 isopropyl MgBr 35 
2 isopropenyl MgBr 45 
3 Ethyl MgBr 15 
4 1-Propenyl MgBr 13 
5 (1,3-dioxolan-2-yl methyl) MgBr No desired product 
*All reactions performed on a 1 mmol scale of aryl halide 69 with geranyl bromide (56, 4 eq), THF (0.2 
M), n-BuLi (2.4 eq) and Li2CuCl4. 
 
Table 8 Concentration study optimization table.  
 
 
Entry Scale (mmol) Conc. [M] Yield (%) 
1 6.5 0.2 55 (38) 
2 3.5 0.2 20 
3 1 0.15 14 
4 1 0.2 19 
5 1 0.25 33 
6 1 0.3 58 
7 7 0.3 38 
8 1 1 20 
9 1 2 47 
10 0.5* 0.2 N.R 
11 0.5** 0.2 messy 
12 1† 0.3 22.5 
13 1‡ 0.3 10 
Parenthesis= average yield; * w/o n-BuLi; ** w/o isopropenyl MgBr; † Stirred for 1 hour at room temp; ‡ 
Stirred overnight at room temp.  
 
Successful acquisition of the coupled geranyl aryl system (70) prompted the 
application of the strategies elucidated for the formation of the cyclohexyl unit allowing 
for functionalization at the terminal end of the geranyl-aryl system (Figure 24). The geranyl 
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sulfone (75) system is the point of divergence in the adopted modular strategy allowing for 
the formation of targets 28, 29, 30 and callophycolide A. It is also important to note that 
this strategy can be adopted to access C. serratus natural products.  
 
 
Figure 23 Scheme for allyl-aryl coupling with optimal conditions quenched with D2O to determine if the 
aryl organometallic complex was forming compound 71 upon deprotonation of an acidic proton within the 
desired product, 70. No deuterium was observed to be incorporated into compound 70.  
 
Allylic oxidation of 70 provided 73 in poor yields, 24%, despite efforts to increase 
the yield. These reactions are inherently low yielding and historically perform badly. 
However, starting material can be recovered and subjected to the oxidation conditions to 
help atom economy. All being said and done, enough material was generated to push 
forward allowing for the formation of allyl bromide 74 in excellent yields, 93%. 
Construction of aryl geranyl sulfone 75 occurred without any difficulty for the exception 
of the observation of the competing SN2’ product which accounts for the slightly 
diminished yield of 87% (Figure 24). 
 
Figure 24 Sequence of steps leading to key intermediate (75, point of divergence) for the synthesis of 





As mentioned above, 75 is the point of divergence towards accessing 
bromophycolides P, Q, U and callophycolide A. The overarching strategy entails the use 
of 75 in a sulfone stabilized anionic epoxide ring opening event to join 75 to either the 
pyran (B , 78) moiety or linalool (D, 76) derivative featured in Figure 25. 77 is a precursor 
for callophycolide A and 79 a precursor for 28, 29, 30. 
 
 






2.2.3 Linalool Fragment- Callophycolide A
 
Figure 26 Initial scheme for the formation of the linalool fragment, precursor for callophycolide A 33.  
 
Construction of the linalool fragment (76, Figure 25) to be joined with 75 began by 
performing an asymmetric Sharpless epoxidation on geraniol 42 (Figure 26). Epoxide 
formation (80) was followed by a primary hydroxyl tosylation and subsequent epoxide ring 
opening promoted with catalytic toluenesulfonic acid (81). Formation of terminal epoxide 
82 occurred with an observation of isolable diastereomers (Figure 26) 33. Successful 
acquisition of 82, linalool epoxide, allowed for a protecting group screen to be performed 
to determine which protecting group can tolerate the sulfone stabilized anionic epoxide 
ring opening event proposed in Figure 25. Figure 27 presents the synthetic scheme for three 
protecting groups appended to the linalool epoxide system which were then subjected to 
the sulfone stabilized anionic epoxide ring opening conditions 34, 35. 
 
Figure 27 Linalool epoxide protecting group screen precursors 34, 35. 
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2.2.4 Sulfone Stabilized Anionic Epoxide Ring Opening 
 
Figure 28 Retrosynthesis for sulfone stabilized anionic ring opening  
Inspiration for the connection of the pyran (78) and linalool (76) scaffold with 75 
(point of divergence) arose from the work of B. Trost (1988) (Figure 28 and Figure 29). 
This entailed deprotonation of a proton alpha to the an isoprenyl/allylic sulfone and 
subsequent nucleophilic attack on a terminal epoxide inevitably joining two units. The 
sulfone forms a dianion when treated with at least 2 eq of n-BuLi which coordinates with 
the hydroxyl (formerly incorporated into the epoxide) providing the stereoselectivity 
desired for target bromophycolides and callophycolide A. Initial test reactions with model 
system 87 and styrene oxide, 88, were promising and illustrated that the transformation can 








Figure 30 Initial attempts to apply Trost’s chemistry to C. serratus natural product point of divergence 
precursor, compound 75. 
 
Initial attempts to apply Trost’s chemistry to C. serratus sulfone 75 by using 
commercially available styrene oxide showed modest yields. Although the transformation 
is not ideal, an unfruitful attempt was made to couple 75 with MOM protected linalool 
epoxide, 83 Figure 30). It is speculated that the oxygen within the MOM protecting group 
disrupts the chelation necessary for the reaction to proceed down the desired pathway. 
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Considering the possibility of chelation disruption, benzyl (84) and dimethylphenyl 
silane (85, DMPS) protecting groups on linalool epoxide were screened using model 
sulfone 87. Use of 87 provided modest results forming 92. No reactivity was observed for 
the for the formation of 93 from 85 probably due to steric hindrance associated with the 
use of the bulky silane protecting group (Figure 31). Considering the possibility that the 
benzyl protecting group might be efficient for the transformation led to attempting the 
coupling of 84 with 75 (Figure 32). There was no evidence of product formation.  
 
 

















Figure 33 Synthetic route to accessing the pyran module for bromophycolides P, Q, and U 37, 39. 
 
 
Formation of the pyran module has been worked out by Vidari and co-workers 
(2000) 37. The multi-step synthesis began with a Sharpless dihydroxylation of geranyl 
acetate, 36, forming diol 95 39. The less sterically hindered alcohol was selectively 
protected using 1-naphthyl isocyanate providing compound 96. Saponification of the 
acetate yielded the primary alcohol handle essential for the subsequent Sharpless 
epoxidation 98 (Figure 33) 37. The remainder of the synthesis was placed on hold while the 
stereochemistry for the dihydroxylation was confirmed via use of Mosher ester analysis. 
 
 
Figure 34 Mosher ester formation for 1H NMR analysis to confirm the correct stereochemistry of diol 




Mosher ester analysis began with the synthesis of the esters from diol, 102, and acyl 
chlorides R-MTPA-Cl and S-MTPA-Cl forming esters 103 and 101 respectively (Figure 
34) 38. It is important to note that the S-acyl chloride forms the R-ester and the R-acyl 
chloride forms the S-ester. Unambiguous assignment for each peak of each diastereomeric 
ester in the 1H NMR was essential for subsequent calculations which use the effects of 
differences in anisotropy and shielding of the Mosher ester appendages on the diol substrate 
to determine the absolute stereochemistry of the substrate in question, 102. The use of 
Chan-Ingold Prelog convention to assign the absolute configuration confirmed formation 
of the S-diol (95, Figure 33) (Table 9). 
 




   (S - R) 
Proton  R-ester (ppm) S-ester (ppm) ppm 
Hz  
(400 MHz) 
i 1.172 1.214 0.042 16.8 
i'  1.138 1.154 0.016 6.4 
e 4.994 4.986 -0.008 -3.2 
g 2.058 2.046 -0.012 -4.8 
d 4.579 4.555 -0.024 -9.6 
h 1.655 1.61 -0.045 -18 
c 5.31 5.259 -0.051 -20.4 
k' 1.74 1.663 -0.077 -30.8 
k 1.882 1.784 -0.098 -39.2 





Carrying forward with this project entails the continuing construction of the pyran 
moiety outlined in Figure 33. An alternative route which could access the pyran more 
readily involves chiral resolution of commercially available 105 and subsequent epoxide 
formation using either Shi conditions or DMDO as a reagent (Figure 35).  Chiral resolution 
is envisioned to occur by forming a boc-protected phenyl alanine in hope that the 
diastereomers can be isolated.  
 
Figure 35 Alternative route for accessing the pyran system for targets bromophycolide P, Q, and U.  
 
 Additionally, optimization for the sulfone stabilized anionic epoxide ring opening 
transformation featured in Figure 25 is required for a successful synthesis. Optimization of 
this step will allow for the synthesis of targets bromophycolides P, Q, U and callophycolide 
A in 3-4 steps. Desulfurization of the product resulting from the anionic ring opening event 
can occur with either sodium amalgam or superhydride (Figure 36). Figure 32 describes 
the final steps needed to complete the scaffold for callophycolide A. It is important to note 
that these transformations can also be applied to completing bromophycolides P, Q, and U. 
Formation of the macrolactone can occur by use of Corey-Nicolaou (via double activation 
of the ester) or Yamaguchi (via formation of a mixed anhydride) macrolactonization 
conditions (Figure 37). Both condition call for extremely dilute conditions (0.001- 0.002 
M). Deprotection of the final precursor should provide C. serratus natural products 
















Figure 37 Final steps towards the completion of the synthesis of callophycolide A. The methods applied to 







 I was successful in obtaining the cyclohexyl module in 5 steps with an overall yield 
of 29%. Methods have been explored for the selective alkene formation of the cyclohexyl 
unit. With Swern elimination conditions selectively forming the exo-cyclic alkene. Use of 
heterogenous Amberlyst-15 dry resin allows for the selective generation of the tri-
substituted alkene. Although these findings are useful, BDSB cyclization of sulfone 46 
forms the tri-substituted alkene. Formation of the tri-substituted alkene is more desirable 
over the exo-cyclic and tetra-substituted alkene due to its increased bio-activity. Joining of 
the aryl and geranyl system using an in situ generate magnesate complex was optimized. 
This entailed finding a method which allowed for the facile generation of the geranyl 
coupling substrate, a phenolic protecting group that would withstand magnesate conditions, 
and concentrations for optimal product recovery.  
Despite my efforts, I was unable to complete the synthesis of targeted 
bromophycolides P, Q, U and callophycolide A. This was due to difficulty encountered 
when attempting to join key units which would allow for the conjoining of the three 
modules that compose the scaffold of the targets. Steps to efficiently perform the sulfone 
stabilized anionic epoxide ring opening event need to be elucidated. Once the three 
modules are joined, macrolactonization would close the system brining the project to its 






CHAPTER 3- EXPERIMENTAL 




Under an inert atmosphere, a solution of TEA (3.62 mL, 26 mmoles, 2 eq) in DCM (25 
mL, 0.52 M) was prepared followed by the addition of 42 (2.00 g, 13 mmoles, 1 eq). The 
resulting solution was stirred at 0° C and TFAA (2.35 mL, 16.9 mmoles, 1.3 eq) was added 
dropwise and then stirred for 30 minutes. Upon reaction completion, the mixture was 
quenched with cold water and extracted with DCM. Combined organic layers were then 
treated with brine, dried over magnesium sulfate, filtered and concentrated. Purification 
was attempted with vacuum distillation but was unsuccessful (b.p.= 72° C, 2 mm Hg). 
Crude 1H-NMR (400 MHz, CDCl3) δ 5.40 (dt, J = 1.2 Hz, 7.4 Hz, 1H), 5.07 (t, J = 2.7 Hz, 




Under an inert atmosphere a solution of DMAP (139 mg, 1.14 mmoles, 0.02 eq) and TEA 
(11.5 mL, 114 mmoles, 1.5 eq) in DCM (120 mL, 0.47 M) was prepared followed by the 
addition of 42 (8.79 g, 57 mmoles, 1 eq). The resulting solution was stirred at 0°C and 
acetic anhydride (6.46 mL, 68.4 mmoles, 1.2 eq) was added and then stirred for 20 minutes. 
Upon reaction completion, the mixture was quenched with water and extracted with DCM. 
Combined organic layers were then treated with 1M HCl, saturated NaHCO3 (aq), brine, 
dried over magnesium sulfate, filtered and concentrated. Purification using flash column 
chromatography provided 36 in 90% yield: Rf = 0.63 (15% EtOAc/Hexane, resolved with 
vanillin stain) 1H-NMR (400 MHz, CDCl3) δ 5.32 (t, J = 7.10 Hz, 1H), 5.07 (t, J = 5.38 Hz, 
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Under an inert atmosphere. A solution of 42 (20.0 g, 130 mmoles, 1 eq), p-TsOH•H2O 
(0.24 g, 1.3 mmoles, 0.01 eq) and 3,4-dihydropyran (16.4 g, 195 mmoles, 1.5 eq) in DCM 
(130 mL, 1 M) was prepared and stirred at room temperature for 3 hours. Upon reaction 
completion, the mixture was quenched with water and extracted with diethyl ether. 
Combined organic layers were then washed with water (3x), brine, and dried over sodium 
sulfate, filtered and concentrated. Purification using flash column chromatography 
provided 43 in 92% yield: Rf= 0.73 (20% EtOAc/Hexane, resolved with vanillin stain) 
1H-
NMR (400 MHz, CDCl3) δ 5.35 (t, J = 6.74 Hz, 1H), 5.09 (t, J = 6.38 Hz, 1H), 4.62 (s, 
broad, 1H), 4.24 (dd, J = 6.4 Hz, 11.84 Hz, 1H), 4.03 (dd, J = 7.5 Hz, 11.8 Hz, 1H), 3.89 
(t, J = 8.2 Hz, 1H), 3.51 (m, 1H), 2.09 (m, 2H), 2.05 (m, 2H), 1.83 (m, 1H), 1.74, (m, 1H), 





Salicylic acid (0.49 g, 3.6 mmoles, 0.1 eq), SeO2 (118.7 mg, 1.08 mmoles, 0.03 eq) then 
DCM (53.4 mL, 0.62 M) was added to a flask at room temperature. TBHP (14.18 mL, 90 
mmoles, 2.5 eq, 70% in H2O) was added to the resulting solution and stirred for 15 minutes. 
The substrate, 36 (7.0 g, 36 mmoles, 1 eq), was then added and the mixture was stirred for 
20 hours. Flask contents was then concentrated under reduced pressure below 30° C. The 
residue was then diluted in Et2O and the organic layer was then washed with 10% KOH 
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(3x), H2O (3x), and brine (1x). The ether layer was then dried over magnesium sulfate, 
filtered and concentrated. Purification using chromatography provided 44 in 49% yield: Rf 
= 0.16 (15% EtOAc/Hexane, resolved with vanillin stain) 1H-NMR (400 MHz, CDCl3) δ 
5.34 (m, 2H), 4.59 (d, J = 7.04 Hz, 2H), 3.99 (s, 2H), 2.16 (m, 2H), 2.10 (m, 2H), 2.05 (s, 






Under an inert atmosphere, make a solution of the alcohol substrate 44 (5.09 g, 24 mmoles, 
1 eq) in DCM (99 mL, 0.24 M). The resulting solution was then cooled to -40° C then TEA 
(6.69 mL, 48 mmoles, 2 eq) was added to the vessel. MsCl (3.72 mL, 48 mmoles, 2 eq) 
was then added to the flask dropwise then stirred for 90 minutes. Get the flask to -15 °C 
then add a solution of LiBr (5.21 g, 60 mmoles, 2.5 eq) in THF (60 mL, 1 M) and stir the 
resulting solution overnight. Quench with saturated NH4Cl (aq), extract with DCM, dry 
over sodium sulfate, filter, and concentrate. 47 was provided in 93% yield. Rf= 0.73 (15% 
EtOAc/Hexane, resolved with UV and vanillin stain) 1H-NMR (400 MHz, CDCl3) δ 5.51 
(dt, J = 6.66 Hz, 33.84 Hz, 1H), 5.34 (t, J = 7.09 Hz, 1H), 4.59 (d, J = 7.10 Hz, 2H), 4.00 
(s, 1 H), 3.96 (s, 1H), 2.16 (m, 2H), 2.10 (m, 2H), 2.05 (s, 3H), 1.75 (d, J = 9.43 Hz, 3H), 
1.70 (s, 3H); 13C-NMR (400 MHz, CDCl3) δ 171.2, 141.5, 132.2, 130.0, 118.9, 61.3, 52.4, 
38.7, 26.2, 24.1, 16.5, 14.2 
 
 
Under an inert atmosphere, stir NaSO2Ph (3.37 g, 19 mmoles, 2.5 eq) in DMSO (105 mL, 
0.1 M) until complete dissolution. Add bromide substrate 47 (2.09 g, 7.6 mmoles, 1 eq) 
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slowly and stir resulting solution at room temperature for 1 hour. To stop reaction, add 
water, extract desired product into DCM, wash with brine (2x), dry over magnesium 
sulfate, filter, concentrate and purify. Purification with flash column chromatography 
provided 46 in 95% yield. Rf= 0.16 (20% EtOAc/Hexane, resolved with UV and vanillin 
stain) ) 1H-NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.68 Hz, 2H), 7.63 (t, J = 7.24 Hz, 1H), 
7.54 (t, J = 7.44 Hz, 2H), 5.18 (t, J = 6.88 Hz, 1H), 4.97 (t, J = 6.86 Hz, 1H), 4.49 (d, J = 
7.00 Hz, 2H), 3.66 (s, 2H), 2.03 (m, 5H), 1.83 (m, 2), 1.76 (s, 3H), 1.64 (s, 3H), 1.57 (m, 
1H); 13C-NMR (400 MHz, CDCl3) δ 171.1, 141.2, 138.4, 135.4, 133.5, 128.9, 128.9, 128.5, 
123.7, 118.8, 66.1, 61.2, 38.4, 26.4, 21.0, 16.7, 16.4.  
 
 
Under an inert atmosphere to a flask at -30 °C, add Et2S (1.2 mL, 11 mmoles, 1.1 eq) and 
SbCl5 (12 mL, 12 mmoles, 1 eq, 1 M in DCM) to a solution of Br2 (0.5 mL, 10 mmoles, 1 
eq) in dry 1,2- DCE (30 mL, 0.33 M). Stir for 30 minutes then gently warm until complete 
dissolution is observed (30-40 °C). Slowly cool solution to -20 °C. Decant solvent keeping 
product (light orange plates). Rinse plates with cold DCM and remove excess solvent under 
vacuum. Store under inert atmosphere at -20 °C. Melting point = 100 °C 
 
BDSB Cyclization Study (Table 4) 
 
General BDSB Cyclization Procedure: Under an inert atmosphere. Make a solution of 
BDSB (0.6 mmol, 1.1 eq) in freshly distilled NO2Me (15 mL, 0.04 M) cooled to 0° C. 
Make another solution of cyclization substrate (0.5 mmol, 1 eq) in NO2Me (15 mL, 0.03 
M) cooled to 0° C. Quickly add BDSB/NO2Me solution to cyclization substrate/NO2Me 
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solution and stir for 5 minutes. Quench reaction with 5% Na2SO3 (aq): 5% Na2SO3 (aq) 
(1:1) and stir for 15 minutes. Pour resulting mixture into water and extract with DCM. 
Combined organic layers dried over magnesium sulfate, filtered, concentrated and purified 
via flash column chromatography. *Concentration varied by altering the amount of 
nitromethane used in the cyclization substrate nitromethane solution. 
 
 
1H-NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.36 Hz, 2H), 7.61 (t, J = 7.36 Hz, 1H), 7.51 (t, 
J = 7.80 Hz, 2H), 5.05 (t, J = 7.12 Hz, 1H), 4.51 (dd, J = 3.64 Hz, 12.20 Hz, 1H), 4.28 (dd, 
J = 8.80 Hz, 12.20 Hz, 1H), 4.08 (m, 1H), 3.69 (s, 2H), 2.2 (m, broad 1H), 2.07 (m, 5H), 
1.74 (m, 4H), 1.65 (s, 1H), 1.48 (m, 1H), 1.34 (m, 1H), 1.26 (s, 2H); 13C-NMR (500 MHz, 
CDCl3) δ 171.28, 170.5, 138.2, 138.1, 135.3, 134.8, 133.6, 133.5, 128.9, 128.8, 128.3, 
124.9, 123.8, 75.2, 73.1, 72.2, 66.2, 65.9, 65.3, 60.5, 40.5, 38.4, 29.5, 26.6, 24.5, 23.7, 23.5, 




1H-NMR (500 MHz, CDCl3) δ 5.51 (t, J = 7.12 Hz, 1H), 4.58 (dd, J = 3.85 Hz, 12.20 Hz, 
1H), 4.50 & 3.83 (dd, J = 2.55 Hz, 11.60 Hz, dd, J = 2.52 Hz, 8.22 Hz, 1H), 4.32 (dd, J = 
8.65 Hz, 12.20 Hz, 1H), 4.15 (m, 1H), 3.99 (s, 2H), 2.35-2.12 (m, 4H), 2.09 (s, 3H), 2.05-
2.01 (m, 1H), 1.89-1.77 (m, 2H), 1.75-1.66 (m, 6H), 1.63-1.58 (m, 1H), 1.34 (s, 11H) 13C-
NMR (500 MHz, CDCl3) δ 171.4, 170.6, 133.0, 132.7, 132.4, 129.6, 128.5, 75.8, 73.4, 
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72.6, 66.3, 65.3, 60.8, 52.0, 41.2, 40.8, 38.6, 26.9, 24.5, 24.2, 24.0, 21.8, 20.8, 14.6, 14.1, 
14.0 HRMS (ESI) m/z: Calcd. For C12H20Br2O3 371.98; Found 372.3 
 
 
Selective Elimination Study (Table 5) 
 
Swern Oxidation: Under an inert atmosphere. Make a solution of dry DMSO (0.11 mL, 
1.68 mmoles, 4.8 eq) in dry DCM (3.6 mL, 0.45 M) and get solution to -78° C. In another 
flask make a solution of (COCl)2 (0.10 g, 0.84 mmoles, 2.4 eq) in dry DCM (0.9 mL, 0.9 
M). Add oxalyl chloride to cooled flask slowly, temperature should not rise above -60° C. 
Stir the resulting mixture for 10 minutes then add solution of cyclized substrate, 37, (0.100 
g, 0.35 mmoles, 1 eq) in dry DCM (3.7 mL, 0.09 M). After stirring for 20 minutes TEA 
(0.23 mL, 1.75 mmoles, 5 eq) was added and stirred for an additional 15 minutes. Gently 
bring the flask to room temperature over a period of 1.5 hours. Once the flask is at room 
temperature concentrate the contents then dissolve the residue in diethyl ether, filter the 
contents, concentrate and purify. Purification using flash column chromatography provided 
the elimination product Rf= 0.75 (20% EtOAc/Hexane, resolved with vanillin stain)   
 
Swern Elimination: Under an inert atmosphere. Make a solution of dry DMSO (0.33 mL, 
4.75 mmoles, 9.5 eq) in dry DCM (1.9 mL, 2.5 M) and get solution to -60° C. In another 
flask make a solution of (COCl)2 (0.22 mL, 2.65 mmoles, 5.3 eq) in dry DCM (5 mL, 0.53 
M). Add oxalyl chloride to cooled flask slowly, temperature should not rise above -60° C. 
Stir the resulting mixture for 5 minutes then add solution of cyclized substrate (146 mg, 
0.5 mmoles, 1 eq) in dry DCM (1 mL, 0.5 M). After stirring for 45 minutes TEA (1.67 mL, 
12 mmoles, 24 eq) was added and stirred for an additional 10 minutes. Gently bring the 
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flask to room temperature over a period of 1.5 hours. Once the flask is at room temperature 
water was added and extracted with diethyl ether. Combined ether extracts were then 
washed with water (2x), NaHCO3 and water. The organic layer was then dried over sodium 
sulfate, concentrated and purified. Purification using flash column chromatography 
provided the elimination product Rf= 0.75 (20% EtOAc/Hexane, resolved with vanillin 
stain) 
 
Ambrlyst-15 dry Elimination: Under an inert atmosphere. Ambrlyst-15 dry resin added 
to flask along with cyclized substrate (0.102 g, 0.35 mmoles, 1 eq) and DCM (20 mL, 0.02 
M). Upon reaction completion flask contents filtered, concentrated and purified. 
Purification using flash column chromatography provided the elimination product Rf= 0.75 









3.2 Aryl- Allyl Cross-Coupling  
 
 
Under an inert atmosphere. A solution of geraniol (5.39 g, 35 mmoles, 1 eq) and pyridine 
(0.22 mL, 2.8 mmoles, 0.08 eq) in diethyl ether (44 mL, 0.8 M) was made and the resulting 
solution was stirred at 0°C.  PBr3 (17.5 mL, 17.5 mmoles, 0.5 eq, 1M solution in DCM) 
was then added slowly over a period of 15 minutes and the resulting solution was then 
stirred for an additional 15 minutes. Upon reaction completion, the resulting yellow 
mixture was then decanted into ice cold water and solid washed with hexane, adding the 
hexane wash to ice cold water. Further extraction from cold water was accomplished with 
diethyl ether and the combined organic layers were then washed with brine (6x) and dried 
over magnesium sulfate. The product was carried forward without any additional 
purification. 56 was formed in 93% yield: Rf = 0.78 (100% Hexane, resolved with vanillin 
stain) 1H-NMR (400 MHz, CDCl3) δ 5.52 (dt, J = 1.04 Hz, 8.44 Hz, 1H), 5.06 (m, 1H), 
4.01 (d, J = 8.44 Hz, 2H), 2.07 (m, 4H), 1.72 (s, 3H), 1.67 (s, 3H), 1.59 (s, 3H) ; 13C-NMR 




Under an inert atmosphere. A solution was made of 59 (2.02 g, 10 mmoles, 1 eq) and 
carbonyl diimiazole (CDI, 2.43 g, 15 mmoles, 1.5 eq) in DMF (6.0 mL, 1.6 M). The 
mixture was then heated to 43° C for 3 hours then treated with tert-butanol (2.85 mL, 30 
mmoles, 3 eq) and DBU (1.5 mL, 10 mmoles, 1 eq) and stirred for 48 hours. Upon reaction 
completion, the solution was diluted with diethyl ether and the organic layer washed with 
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1 M HCl, water, saturated K2CO3 (aq), dried over sodium sulfate, filtered, concentrated 
and purified. Purification using flash column chromatography provided tert-butyl 4-
bromobenzoate in 52% yield: Rf = 0.66 (20% EtOAc/Hexane, resolved with UV) 
1H-NMR 
(400 MHz, CDCl3) δ 7.83 (d, J = 8.56 Hz, 2H), 7.54 (d, J = 8.52 Hz, 2H), 1.58 ( s, 9H); 
13C-NMR (400 MHz, CDCl3) δ 165.00, 131.47, 130.99, 130.91, 127.42, 81.47, 28.15 
 
 
Under an inert atmosphere to a flask cooled to 0° C a solution of isopropylmagnesium 
bromide (1.2 mL, 1.2 mmoles, 1.2 eq, 1 M solution in THF) in THF (2 mL, 0.6 M) was 
made. n-Butyl lithium (0.96 mL, 2.4 mmoles, 2.4 eq, 2.3 M solution in hexanes) was added 
to reaction vessel and stirred for 10 minutes. The flask was then brought to -78° C and a 
solution of 60 (0.25 g, 1 mmole, 1 eq) in THF (2 mL, 0.5 M) was added dropwise and 
stirred for 1 hour. CuCN•2LiCN (0.3 mL, 0.3 mmoles, 0.3 eq, 1 M solution in THF) was 
then added to the reaction vessel followed by 61 (0.48 g, 4 mmoles, 4 eq). The solution 
was then stirred for 0.5 hour and quench with saturated NH4Cl (aq) and the flask was gently 
brought to room temperature. After addition of a small amount of water to break-up the 
emulsion, the aqueous layer was extracted with hexane, combined organic extracts dried 
over sodium sulfate, filtered, concentrated and purified. Purification using flash column 
chromatography provided 62 in 51% yield: Rf = 0.56 (20% EtOAc/Hexane, resolved with 
UV) 1H-NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.25 Hz, 2H), 7.22 (d, J = 8.35 Hz, 2H), 
5.94 (dtq, J = 27.06 Hz, 6.67 Hz, 6.58 Hz, 1H), 5.07 (d, J = 8.10 Hz, 2H), 3.42 (d, J = 6.65 
Hz, 2H), 1.59 (s, 9H); 13C-NMR (500 MHz, CDCl3) δ 165.60, 144.71, 136.39, 129.76, 






A solution was made of 63 (2.17 g, 10 mmoles, 1 eq) in methanol (12.9 mL, 0.8 M). 
Sulfuric acid (0.1 mL, 2 mmoles, 0.2 eq) was added to the reaction vessel and the contents 
then stirred for 16.5 hours. Upon completion, the solution was concentrated and the residue 
dissolved in ethyl acetate, washed with saturated NaHCO3 (aq, 3x), brine, dried over 
sodium sulfate, filtered, concentrated and purified. Purification using flash column 
chromatography provided 64 in 88% yield: Rf = 0.62 (50% EtOAc/Hexane, resolved with 
UV) 1H-NMR (400 MHz, CDCl3) δ 8.19 (d, J = 1.96 Hz, 1H), 7.92 (dd, J = 10.52 Hz, 6.56 
Hz, 1H), 7.05 (d, J = 8.52 Hz, 1H), 5.94 (s, 1H), 3.89 (s, 3H); 13C-NMR (400 MHz, CDCl3) 
δ 165.59, 156.15, 133.92, 131.04, 124.07, 115.78, 110.09, 52.21 
 
Under an inert atmosphere. A solution of the 64 (1.61 g, 7 mmoles, 1 eq) in DCM (35 mL, 
0.2 M) was made by gently heating to 40-50° C to facilitate complete dissolution. TIPSCl 
(1.79 mL, 8.4 mmoles, 1.2 eq) and N(iPr)2Et (3.65 mL, 21 mmoles, 3 eq) were then added 
to the reaction vessel and the resulting solution stirred for 3.5 hours at room temperature. 
Upon completion, the solution was washed with saturated NH4Cl (aq), NaHCO3, brine, 
dried over magnesium sulfate, filtered, concentrated and purified. Purification using flash 
column chromatography provided 65 in 100% yield: Rf = 0.5 (20% EtOAc/Hexane, 
resolved with UV) 1H-NMR (400 MHz, CDCl3) δ 8.22 (d, J = 2.08 Hz, 1H), 7.86 (dd, J = 
2.10 Hz, 8.50 Hz, 1H), 6.90 (d, J = 8.52, 1H), 3.88 (s, 3H), 1.38-1.30 (m, 3H), 1.13 (d, J = 
7.40 Hz, 18H); 13C-NMR (400 MHz, CDCl3) δ 165.8, 157.1, 135.1, 130.1, 123.9, 118.9, 






Under an inert atmosphere, a solution of 63 (2.17 g, 10 mmoles, 1 eq) and DMAP (0.06 g, 
0.5 mmoles, 0.05 eq) in tert-butanol (63 mL, 0.16 M) was made. A solution of DCC (2.47 
g, 12 mmoles, 1.2 eq) in THF (21 mL, 0.47 M) was then added to the reaction vessel and 
the resulting mixture stirred for 12 hours. The contents of the flask were then concentrated 
under reduced pressure and the residue dissolved in diethyl ether (211 mL, 0.05 M) and 
stirred with oxalic acid (2.7 g, 30 mmoles, 3 eq). The resulting mixture was then filtered 
through a short pad of silica. The filtrate was then washed with saturated NaHCO3 (aq), 
water, brine, dried over sodium sulfate, filtered, concentrated and purified. Purification 
using flash column chromatography provided 66 in 88% yield: Rf = 0.35 (20% 
EtOAc/Hexane, resolved with UV) 1H-NMR (400 MHz, CDCl3) δ 8.11 (d, J = 2.00 Hz, 
1H), 7.86 (dd, J = 2.02 Hz, 8.50 Hz, 1H), 7.02 (d, J = 8.52 Hz, 1H), 5.95 (s, 1H), 1.57 (s, 
9H); 13C-NMR (400 MHz, CDCl3) δ 164.29, 155.74, 133.71, 130.85, 125.92, 115.56, 




Under an inert atmosphere. A solution of the substrate (2.32 g, 8.5 mmoles, 1 eq) in THF 
(42.5 mL, 0.2 M) was made. TIPSCl (1.96 g, 10.2 mmoles, 1.2 eq) and N(iPr)2Et (3.29 g, 
25.5 mmoles, 3 eq) were then added to the reaction vessel and the resulting solution stirred 
for 5 hours at room temperature. Upon completion, the solution was washed with saturated 
NH4Cl (aq), NaHCO3, brine, dried over magnesium sulfate, filtered, concentrated and 
purified. Purification using flash column chromatography provided tert-butyl 3-bromo-4-
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((triisopropylsilyl)oxy)benzoate in 100% yield: Rf = 0.8 (20% EtOAc/Hexane, resolved 
with UV) 1H-NMR (400 MHz, CDCl3) δ 8.14 (d, J = 2.16 Hz, 1H), 7.80 (dd, J = 2.16 Hz, 
8.52 Hz, 1H), 6.87 (d, J = 8.52 1H), 1.56 (s, 9H), 1.33 (m, 3H), 1.13 (d, J = 7.36 Hz, 18H); 




Under an inert atmosphere to a flask cooled to 0° C a solution of isopropylmagnesium 
bromide (0.6 mL, 0.6 mmoles, 1.2 eq) in THF (0.6 M) was made. n-Butyl lithium (0.5 mL, 
1.2 mmoles, 2.4 eq) was added to reaction vessel and stirred for 10 minutes. The flask was 
then brought to -78° C and a solution of 67 (0.212 g, 0.5 mmoles, 1 eq) in THF (2 mL, 0.5 
M) was added dropwise and stirred for 1 hour. CuCN•2LiCN (0.15 mL, 0.15 mmoles, 0.3 
eq, 1 M solution in THF) was then added to the reaction vessel followed by geranyl 
bromide (0.43 g, 2 mmoles, 4 eq). The solution was then stirred for 0.5 hour and quench 
with saturated NH4Cl (aq) and the flask was gently brought to room temperature. After 
addition of a small amount of water to break-up the emulsion, the aqueous layer was 
extracted with hexane, combined organic extracts dried over sodium sulfate, filtered, 
concentrated and purified. Purification using flash column chromatography provided tert-
butyl 4-hydroxy-3-(triisopropylsilyl)benzoate in 89% yield: Rf = 0.44 (5% EtOAc/Hexane, 
resolved with UV) 1H-NMR (400 MHz, CDCl3) δ 8.10 (d, 1H), 7.87 (dd, 1H), 6.70 (d, 1H), 








Under an inert atmosphere, a solution was made consisting of 66 (1.50 g, 5.5 mmoles, 1 
eq), potassium carbonate (3.80 g, 27.5 mmoles, 5 eq), and methyl iodide (8.36 mL, 55 
mmoles, 10 eq) in acetone (22 mL, 0.25 M). The resulting solution was stirred at reflux for 
6 hours. Upon reaction completion, the mixture was cooled, filtered, concentrated and 
purified. Purification using flash column chromatography provided 69 in 97% yield: Rf = 
0.52 (20% EtOAc/Hexane, resolved with UV) 1H-NMR (400 MHz, CDCl3) δ 8.15 (d, J = 
2.10 Hz, 1H), 7.93 (dd, J = 2.10 Hz, 8.60 Hz, 1H), 6.89 (d, J = 8.65 Hz, 1H), 3.94 (s, 3H), 
1.57 (s, 9H); 13C-NMR (400 MHz, CDCl3) δ 164.22, 158.88, 134.44, 130.22, 125.49, 




Optimized: Under an inert atmosphere to a flask cooled to 0° C a solution of 
isopropylmagnesium bromide (15.6 mL, 7.8 mmoles, 1.2 eq) in THF (0.3 M) was made. 
n-Butyl lithium (6.78 mL, 15.6 mmoles, 2.4 eq) was added to reaction vessel and stirred 
for 10 minutes. The flask was then brought to -78° C and a solution of 69 (1.86 g, 6.5 
mmoles, 1 eq) in THF (1 M) was added dropwise and stirred for 1 hour. Li2CuCl4 (19.5 
mL, 1.95 mmoles, 0.3 eq, 1 M solution in THF) was then added to the reaction vessel 
followed by 56 (5.16 mL, 26 mmoles, 4 eq). The solution was then stirred for 0.5 hour and 
quench with saturated NH4Cl (aq) and the flask was gently brought to room temperature. 
After addition of a small amount of water to break-up the emulsion, the aqueous layer was 
extracted with hexane, combined organic extracts dried over sodium sulfate, filtered, 
concentrated and purified. Purification using flash column chromatography  in sequence 
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(1st column: 3% EtOAc/Hexane; 2nd column: 1% Et2O/Petroleum ether) provided 70 in 
53% yield: Rf = 0.48 (10% Et2O/Hexane, resolved with UV and vanillin stain) 
1H-NMR 
(500 MHz, CDCl3) δ 7.84 (dd, J = 2.27 Hz, 8.52 Hz, 1H) 7.77 (d, J = 2.15, 1H), 6.83 (d, J 
= 8.60 Hz, 1H), 5.31 (dt, J = 1.25 Hz, 7.30 Hz, 1H), 5.11 (tt, J = 1.37 Hz, 10.26 Hz, 1H), 
3.87 (s, 3H), 3.33 (d, J = 7.25 Hz, 2H), 2.11 (m, 2H), 2.04 (m, 2H), 1.70 (s, 3H), 1.66 (s, 
3H), 1.59 (s, 3H), 1.57 (s, 9H); 13C-NMR (500 MHz, CDCl3) δ 165.7, 160.5, 136.3, 131.1, 





Salicylic acid (30 mg, 0.22 mmoles, 0.1 eq), SeO2 (7 mg, 0.06 mmoles, 0.03 eq) then DCM 
(3.3 mL, 0.62 M) was added to a flask at room temperature. TBHP (0.75 mL, 5.5 mmoles, 
2.5 eq, 70% in H2O) was added to the resulting solution and stirred for 15 minutes. 70 
(0.75 g, 2.2 mmoles, 1 eq) was then added and the mixture was stirred for 20 hours. Flask 
contents was then concentrated under reduced pressure below 30°C. The residue was then 
diluted in Et2O and the organic layer was then washed with 10% KOH (3x), H2O (3x), and 
brine (1x). The ether layer was then dried over magnesium sulfate, filtered and 
concentrated. Purification using chromatography provided tert-butyl 3-((2E,6E)-8-
hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-4-methoxybenzoate in 24% yield: Rf = 0.23 
(20% EtOAc/Hexane, resolved with vanillin stain) 1H-NMR (500 MHz, CDCl3) δ 7.83 (dd, 
J = 2.20 Hz, 8.50 Hz, 1H), 7.77 (d, J = 2.20 Hz, 1H), 6.82 (d, J = 8.60 Hz, 1H), 5.42 (dt, J 
= 1.32 Hz, 6.86 Hz, 1H), 5.32 (dt, J = 1.22 Hz, 7.36 Hz, 1H), 3.98 (d, J = 7.30 Hz, 2H), 
3.87 (s, 3H), 3.33 (d, 2H), 2.20 (m, 2H), 2.12 (m, 2H), 1.77 (t, 1H), 1.69 (s, 3H), 1.64 (s, 
3H), 1.58 (s, 1H), 1.57 (s, 9H); 13C-NMR (500 MHz, CDCl3) δ 165.9, 160.5, 136.1, 134.9, 
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Under an inert atmosphere, a solution of 73 (0.360 g, 1 mmole, 1 eq) in DCM (4.16 mL, 
0.24 M)  was prepared and then cooled to -40°C then add TEA (0.2787 mL, 2 mmoles, 2 
eq). Add MsCl (0.1548 mL, 2 mmoles, 2 eq) dropwise then stir for 90 minutes. Get flask 
to -15 °C then add a solution of LiBr (0.2171 g, 2.5 mmoles, 2.5 eq) in THF (1 mL, 1 M) 
and stir the resulting solution overnight. Quench with saturated NH4Cl (aq), extract with 
DCM, dry over sodium sulfate, filter, and concentrate. Crude 74 was provided in 93% 





Under an inert atmosphere, stir NaSO2Ph (0.4104 g, 2.5 mmoles, 2.5 eq) in DMSO (10 
mL, 0.1 M) until complete dissolution. Add 74 (0.4233 g, 1 mmole, 1 eq) slowly and stir 
resulting solution at room temperature overnight. To stop reaction, add water, extract 
desired product into DCM, wash with brine (2x), dry over magnesium sulfate, filter, 
concentrate and purify. Purification with flash column chromatography provided 75 in 87% 
yield. Rf= 0.34 (20% EtOAc/Hexane, resolved with UV and vanillin stain) 
1H-NMR (500 
MHz, CDCl3) δ 7.82 (d, J = 7.75 Hz, 3H), 7.71 (d, J = 1.95 Hz, 1H), 7.61 (t, J = 7.37 Hz, 
1H), 7.50 (t, J = 7.75 Hz, 2H), 6.83 (t, J = 8.25 Hz, 1H), 5.18 (t, J = 7.25 Hz, 1H), 5.03 (t, 
J = 7.15 Hz, 1H), 3.87 (s, 2H), 3.72 (s, 1H), 3.28 (d, J = 7.30 Hz, 2H), 2.07 (t, J = 7.62 Hz, 
2H), 1.87 (t, J = 7.55 Hz, 2H), 1.75 (d, 2H), 1.62 (s, 2H), 1.59 (s, 1H), 1.57 (s, 9H), 1.55 
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(s, 2H); 13C-NMR (500 MHz, CDCl3) δ 165.7, 160.5, 138.1, 135.6, 135.4, 133.2, 130.3, 
129.3, 128.9, 128.6, 128.3, 123.8, 123.2, 122.1, 109.0, 80.2, 65.9, 55.3, 38.4, 28.0, 27.9, 










































3.3 Linalool Fragment- Callophycolide A 
 
 
Under an inert atmosphere, a solution was prepared containing 82 (0.170 g, 1 mmole, 1 
eq), DIPEA (0.52 mL, 3 mmoles, 3 eq), and DMAP (8 mg, 0.07 mmoles, 0.07 eq) in DCM 
(3.45 mL, 0.3 M). The resulting mixture was then cooled to 0° C and MOMCl (0.16 mL, 
2.1 mmoles, 2.1 eq) was added dropwise. The flask was then gently warmed to room 
temperature and the contents stirred for 16 hours. Upon completion, the contents were then 
poured into 10% citric acid (aq), extracted with DCM and then washed with water and 
brine. The resulting solution was the dried over sodium sulfate, filtered and concentrated 
under reduced pressure below 30° C. Purification using flash column chromatography 
provided 83 in 89% yield Rf = 0.8 (30% EtOAc/Hexane resolved with vanillin and UV) 
1H-NMR (500 MHz, CDCl3) δ 5.10 (t, J = 6.96 Hz, 1H), 4.79 (d, J = 7.28 Hz, 1H), 4.67 (d, 
J = 7.28 Hz, 1H), 3.37 (s, 3H), 2.97 (t, J = 3.30 Hz, 1H), 2.75 (m, 1H), 2.70 (t, J = 4.56 Hz, 
1H), 2.10 (q, J = 8.00 Hz, 2H), 1.68 (s, 3H), 1.61 (s, 3H), 1.21 (s, 3H) ; 13C-NMR (500 
MHz, CDCl3) δ 131.74, 124.17, 91.55, 76.70, 75.72, 57.20, 55.38, 44.0, 37.80, 25.69, 




Under an inert atmosphere, a solution was prepared containing 82 (0.2979 g, 1.75 mmoles, 
1 eq) in THF (9 mL, 0.2 M) and then cooled to 0° C. NaH (0.28 g, 7 mmoles, 4 eq) was 
then added to the reaction vessel and the solution gently warmed to room temperature. 
Recrystallized TBAI (96 mg, 0.26 mmoles, 0.15 eq) and benzyl bromide (0.416 mL, 3.5 
mmoles, 2 eq) were then added to the flask and the contents were stirred for 22 hours. To 
quench the reaction, cool the flask to 0° C then add water slowly. The mixture was then 
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extracted with diethyl ether, dried over sodium sulfate, filtered, concentrated under reduced 
pressure below 30° C and purified. Purification using flash column chromatography 
provided 84 in 89% yield Rf = 0.65 (20% EtOAc/Hexane resolved with vanillin and UV) 
1H-NMR (500 MHz, CDCl3) δ 7.35 (m, 5H), 5.10 (tquint, J = 10.69 Hz, 1.41 Hz, 1H), 4.64 
(dd, J = 11.85 Hz, 52.72 Hz, 2H), 3.70 (dddd, J = 4.50 Hz, 6.07 Hz, 11.20 Hz, 50.37 Hz,  
2H), 3.02 (dd, J = 4.50 Hz, 6.05 Hz, 1H), 2.10 (q, J = 7.67 Hz, 2H), 1.67 (s, 3H), 1.64 (m, 
1H), 1.60 (s, 3H), 1.50 (m, 1H), 1.25 (s, 3H); 13C-NMR (500 MHz, CDCl3) δ 137.7, 131.9, 




Under an inert atmosphere, a solution was prepared containing 82 (170 mg, 1 mmole, 1 
eq), DIPEA (0.52 mL, 3 mmoles, 3 eq), and DMAP (8 mg, 0.07 mmoles, 0.07 eq) in DCM 
(3.44 mL, 0.3 M). The resulting mixture was then cooled to 0° C and DMPSCl (0.35 mL, 
2.1 mmoles, 2.1 eq) was added dropwise. The flask was then gently warmed to room 
temperature and the contents stirred for 16 hours. Upon completion, the contents were then 
poured into 10% citric acid (aq), extracted with DCM and then washed with water and 
brine. The resulting solution was the dried over sodium sulfate, filtered and concentrated 
under reduced pressure below 30° C. Purification using flash column chromatography 85 
in 14% yield Rf = 0.27 (20% EtOAc/Hexane resolved with vanillin and UV) 
1H-NMR (500 
MHz, CDCl3) δ 7.61 (m, 2H), 7.37 (m, 3H), 5.10 (tquint, J = 10.72 Hz, 1.40 Hz, 1H), 2.88 
(dd, J = 2.72 Hz, 3.96 Hz, 1H), 2.71 (dd, J = 2.72 Hz, 5.36 Hz, 1H), 2.61 (dd, J = 3.96 Hz, 
5.36 Hz, 1H), 2.12 (m, 2H), 1.68 (m, 4H), 1.60 (m, 5H), 1.21 (s, 3H), 0.45 (d, J = 3.16 Hz, 
1H), 0.40 (d, J = 3.16 Hz, 4H), 0.34 (d, J = 3.24 Hz, 1H); 13C-NMR (500 MHz, CDCl3) δ 










General Procedure for Sulfone Stabilized Anionic Epoxide Ring Opening: Under an 
inert atmosphere at 0° C, a solution was prepared of the 87 (1 eq) in THF (0.25 M). n-Butyl 
lithium (2.5 eq) was added to the solution, the flask gently warmed to room temperature 
and the resulting solution stirred for 1 hour. The flask was then cooled to -78° C and the 
epoxide (1 eq) was then added to the reaction vessel and the flask gently warmed to room 
temperature over a period of 4 hours. The solution was then stirred for 12- 24 hours. Upon 
completion, the solution was cooled to -78° C and quenched with the addition of 10% 
NaHSO4 (aq). After gently warming the flask to room temperature, the solution was diluted 
with diethyl ether, washed with 10% NaHSO4 (aq), dried over magnesium sulfate, filtered, 
concentrated and purified. Purification using flash column chromatography provided 89 in 



















General Mosher ester procedure: Under an inert atmosphere. A solution was made with 
102 (92 mg, 0.4 mmoles, 1 eq) and pyridine (0.10 mL, 1.24 mmoles, 3.1 eq) in DCM (6.25 
mL, 0.06 M). The Mosher acid chloride (0.191 g, 0.76 mmoles, 1.9 eq) was then added to 
the solution and stirred for 2 hours at room temperature. The contents were then poured 
into a separatory funnel with diethyl ether and water. The aqueous layer was further 
extracted with diethyl ether and combined organic fractions dried over sodium sulfate, 
filtered, concentrated, and purified. Purification using flash column chromatography 
provided 101 in 33% yield Rf = 0.63 (50% EtOAc/Hexane, resolved with vanillin stain); 




1H-NMR (400 MHz, CDCl3) δ 7.59 (m, 2H), 7.41 (m, 3H), 5.29 (dt, J = 1.22 Hz, 7.04 Hz, 
1H), 4.97 (dd, J = 2.24 Hz, 9.88 Hz, 1H), 4.57 (d, J = 7.04 Hz, 1H), 3.55 (s, 4H), 3.21 (br, 
1H), 2.05 (s, 3H), 2.01 (t, J = 7.96 Hz, 2H) 1.86 (m, 1H), 1.69 (m, 1H), 1.65 (s, 3H), 1.17 
(s, 3H), 1.13 (s, 3H); 13C-NMR (400 MHz, CDCl3) δ 171.37, 166.42, 140.75, 131.96, 
129.77, 129.75, 128.54, 128.49, 127.45, 119.19, 82.32, 72.52, 61.29, 55.47, 35.88, 28.12, 






1H-NMR (400 MHz, CDCl3) δ 7.62 (m, 2H), 7.40 (m, 3H), 5.24 (dt, J = 1.24 Hz, 7.06 Hz, 
1H), 4.97 (dd, J = 2.18 Hz, 10.14 Hz, 1H), 4.54 (d, J = 7.08 Hz, 2H), 3.56 (d, J = 1.20 Hz, 
3H) 2.04 (s, 3H), 1.91 (t, J = 7.94 Hz, 2H), 1.74 (m, 1H), 1.65 (m, 2H), 1.62 (m, 3H), 1.21 
(s, 3H), 1.15 (s, 3H) ; 13C-NMR (400 MHz, CDCl3) δ 171.12, 166.93, 140.74, 132.06, 
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